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Background: The aim of this study was to investigate the prognostic significance and various classifications for
anatomic masticator space involvement (MSI) in patients with nasopharyngeal carcinoma (NPC).
Methods: This study retrospectively analyzed 742 patients with untreated nondisseminated NPC who underwent
magnetic resonance imaging (MRI) scan of the nasopharynx and neck. The MSI was graded according to different
anatomic features. The overall survival (OS), local relapse-free survival (LRFS), distant metastasis-free survival (DMFS),
and disease-free survival (DFS) of the patients with different MSI grades were analyzed using the Kaplan-Meier
method and log-rank tests.
Results: The frequency of MSI was 24.1% (179/742). The 5-year OS, LRFS, DMFS, DFS for NPC patients with versus
without MSI were 70.9% versus 82.5% (P = 0.001), 94.1% versus 91.4% (P = 0.511), 81.4% versus 88.7% (P = 0.021),
and 78.0% versus 83.5% (P = 0.215), respectively. Significant differences in OS were also found among different MSI
groups. In the patients with MSI, the OS of the group with medial and/or lateral pterygoid involvement (MLPI) NPC
was 73.9% compared to 51.3% (P < 0.0001) in the patients with infratemporal fossa involvement (IFI).
Conclusions: MSI was an independent prognostic factor for OS and DMFS. NPCs invading the masticator space
should be separately categorized into MLPI and IFI prognostic groups. We suggest that MLPI should be staged as
T3 while IFI is staged as T4 disease in future TNM staging revision.
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Nasopharyngeal carcinoma (NPC) is one of the most
common malignant tumors in southern China and
Southeast Asia with incidences reported as 15-50 per
100,000 in high-incidence areas [1-7].
NPC is an aggressive disease and tends to involve su-
rrounding tissues and organs. The masticator space is one* Correspondence: mohy@sysucc.org.cn
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unless otherwise stated.of the most vulnerable structures. Anatomically, the mas-
ticator space is defined as a deep facial space enclosed by
the superficial layer of deep cervical fasciae, which is lo-
cated in the anterior-lateral side of the parapharyngeal
space. It contains four muscles of mastication: the medial
and lateral pterygoid muscles, the masseter muscle and
the temporalis muscle. The content of the masticator
space also includes the additional structures encompassed
within these fascial boundaries. These structures include
the ramus of the mandible and the third division of the
fifth cranial nerve (CN V) as it passes through the for-
amen ovale into the suprahyoid neck [8-10] (Figure 1A).
The inferior limit of the anatomic masticator space is
the attachment of the medial pterygoid muscle to the. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Normal masticator space and different grades of masticator space involvement in magnetic resonance images. (A) Axial
T2-weighted magnetic resonance (MR) image (1800 ~ 3000 ms/90 ~ 150 ms, TR/TE) at the level of the nasopharynx shows the anatomic masticator
space (circled in red). LP = lateral pterygoid muscle, M = masseter muscle, MP =medial pterygoid muscle, TP = temporalis muscle. (B) Grades of
masticator space involvement. Grade 0: without MSI; Grade 1: with medial pterygoid muscle involvement but without lateral pterygoid muscle
involvement or infratemporal fossa involvement; Grade 2: with medial and /or lateral pterygoid muscle but without infratemporal fossa
involvement; Grade 3: with infratemporal fossa involvement. (C) T1-weighted axial contrast medium–enhanced MR image and (D) T2-weighted
MR image show extensive tumor infiltration in the left masticator space. Medial and lateral pterygoid muscle involvement is marked with a red
asterisk in each image. (E) T1-weighted axial MR image, (F) T1-weighted axial contrast medium–enhanced MR image, and (G) T2-weighted MR
image show left infratemporal fossa involvement (red arrow).
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skull [8,9]. The entire masticator space can be divided
into the supratemporal fossa and intratemporal fossa by
the zygomatic arch, the latter of which is known as an
inherent part of the masticator space. The masticator
space plays an important role in the tumor staging sys-
tem of NPC. Radiology textbooks often use the same
definition of “masticator space” with inclusion of the
medial and lateral pterygoid muscles [11].
Currently, the Chinese 2008 staging system [12] and
the seventh edition American Joint Committee on Can-
cer staging system (AJCC 7th, 2009) [13] are commonly
used in China and abroad. These two new staging sys-
tems possess certain similarities and differences [14].
One of the major differences is varying T stage for mas-
ticator space involvement. The most ambiguous termamong the defining criteria is “masticatory space”. This
was introduced in the 6th edition as a synonym of infra-
temporal fossa, defined as extension beyond the anterior
surface of the lateral pterygoid muscle or beyond the
posterolateral wall of the maxillary antrum and/or the
pterygo-maxillary fissure [15]. Unfortunately, this differs
from the definition used in classical radiological text-
books as “primarily the muscles of mastication (the
medial and lateral pterygoid, masseter and temporalis)
enclosed by the superficial layer of the deep cervical
fascia”, and this description was adopted in the 7th
edition [13,16]. The study by Tang et al. [10] supported
this definition for T4 classification in AJCC 7th edition
due to its significant impact on the overall survival and
local relapse-free survival of patients with NPC. As a
result, the authors recommended that anatomic masticator
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ygoid muscles be classified as stage T4 disease. Accor-
ding to their results, tumors with extension limited to
adjacent pterygoid muscles could be over-staged and
classified as T4. However, these tumors generally have a
much better prognosis, and incorrect staging may lead
to potentially unnecessary treatment. In the Chinese
2008 system, medial and lateral pterygoid muscles were
included in the definition of masticator space, and mas-
ticator space involvement excluding medial pterygoid
muscles was classified as T4, while medial pterygoid in-
volvement was classified as T3 [12].
This study retrospectively analyzed 742 patients with
untreated nondisseminated NPC who underwent MRI
scan of the nasopharynx and neck. The MSI was
graded according to different anatomic features. By
comparing our data with established staging systems,
we aimed to establish an optimal grading method for
masticator space involvement and determine the prog-
nostic value to facilitate treatment strategies in pa-
tients with NPC. The medial and/or lateral pterygoid
involvement is abbrievated as MLPI and infratemporal




We reviewed the records of consecutive NPC patients
referred to Sun Yat-sen University Cancer Center be-
tween January 1, 2005 and December 31, 2005 with his-
tologically proven NPC without distant metastasis. The
cohort consisted of 575 male and 167 female patients,
giving a male: female ratio of 3.44:1. The median patient
age was 46 y (range 16–78 y). Histologically, 717
(96.63%) patients had World Health Organization
(WHO) Type III disease, and 25 (3.37%) had WHO Type
II disease. Table 1 shows the characteristics of all
patients.
This retrospective study was approved by the Clinical
Research Ethics Committee of the Sun Yat-sen Univer-
sity Cancer Centre, and all the participants provided
written informed consent before treatment.
Pretreatment evaluation
The pretreatment patient evaluation included a complete
medical history, physical and neurologic examinations,
hematological studies, and biochemical profiles. All pa-
tients underwent fiberoptic endoscopy of the nasophar-
ynx, oropharynx and larynx and were examined with
magnetic resonance imaging (MRI) of the nasopharynx
and the neck. Biopsies of all primary tumors for histo-
logic diagnosis were performed for all patients before
treatment. The metastatic workup included chest radio-
graphs, abdominal sonography, and a whole body bonescan using single photon emission computed tomog-
raphy (SPECT) or positron emission tomography-
computed tomography (PET/CT). All patients’ clinical
stages were reclassified according to the AJCC 7th edi-
tion staging system.
MR imaging protocol
All patients underwent MRI with a 1.5 T system (Singa
Excite/or HDX 1.5 T, American GE Company). The MRI
was performed on spiral echo (SE) sequence, with scan-
ning directions of cross section, sagittal plane, and cor-
onal plane. The area from the suprasellar cistern to the
inferior margin of the sterna end of the clavicle was ex-
amined with a head-and-neck combined coil in a slice
thickness of 5 mm with 0.5 mm interslice gap. The fol-
lowing MRI sequences were applied: T1-weighted spin
echo images (400–600 ms/15 ~ 25 ms TR/TE), T2-
weighted fast spin echo images (1800 ~ 3000 ms/90 ~
150 ms, TR/TE), and enhanced T1-weighted spin echo
images with gadolinium-DTPA (Gd-DTPA) injection at
a dose of 0.1 mmol/kg body weight.
Image assessment and grades of MSI
All MRI images were reviewed to minimize heterogen-
eity in restaging. Two radiologists specialized in head
and neck cancers independently evaluated all scans. Any
disagreements were resolved by consensus.
The presence of MSI was defined based on MRI find-
ings and by the presence of low-density signal on T1-
weighted images, high signal changes on T2-weighted
images, and enhancement by Gd-DTPA in the mastica-
tor space complex. As described above, the masticator
space complex includes the medial and lateral pterygoid
muscles, the masseter muscle, the temporalis muscle,
and any spaces between them. A diagnosis of MSI is
made if the muscle is indistinguishable from the tumor
mass by signal intensity, if asymmetry in signal intensity
exists, or if the integrity of the muscles of mastication
has been disrupted by the tumor in two orthogonal
views (Figure 1C, D).
Patients without MSI were recorded as grade 0. Pa-
tients with medial pterygoid muscle involvement but
without lateral pterygoid muscle involvement or infra-
temporal fossa involvement recorded as grade 1. Patients
with lateral pterygoid muscle involvement but without
infratemporal fossa involvement recorded as grade 2,
and any infratemporal fossa involvement (IFI) was re-
corded as grade 3 (Figure 1B).
Patient treatment
All patients received radical radiotherapy. Two different
techniques were applied for the patients in different
TNM stages. In this study, 83.6% (620/742) of patients
received two-dimensional conformal radiotherapy, and
Table 1 Patient characteristics categorized by MSI (N = 742)
N = 742 Without MSI With MSI n =180 P Value
0(n = 562) 1(n = 119) 2(n = 38) 3(n = 23)
Age(Y) 0.397
<46 367 279 61 19 8
(49.46%) (49.64%) (51.26%) (50.00%) (34.78%)
> = 46 375 283 58 19 15
(50.54%) (50.36%) (48.74%) (50.00%) (65.22%)
UICC 7th T <0.001
T1, T2 308 292 15 0 0
(41.51%) (51.96%) (12.61%) (0) (0)
T3, T4 434 270 104 38 23
(58.49%) (48.04%) (87.39%) (100%) (100%)
UICC 7th N 0.047
N0, N1 554 413 89 32 20
(74.66%) (73.49%) (74.79%) (84.21%) (86.96%)
N2, N3 188 149 30 6 3
(25.34%) (26.51%) (25.21%) (15.79%) (13.04%)
Chemotherapy <0.001
No 200 184 13 1 2
(26.95%) (32.74%) (10.92%) (2.63%) (8.70%)
Induction 217 143 42 24 8
(29.25%) (25.44%) (35.29%) (63.16%) (34.78%)
Induction + CCRT 112 69 27 8 8
(15.09%) (12.28%) (22.69%) (21.05%) (34.78%)
Induction + Adjuvant 9 8 1 0 0
(1.21%) (1.42%) (0.84%) (0) (0)
CCRT 171 132 32 4 3
(23.05%) (23.49%) (26.89%) (10.53%) (13.04%)
CCRT + Adjuvant 16 13 2 0 1
(2.16%) (2.31%) (1.68%) (0) (4.35%)
Induction + CCRT + Adjuvant 16 12 2 1 1
(2.16%) (2.14%) (1.68%) (2.63%) (4.35%)
Adjuvant 1 1 0 0 0
(0.13%) (0.18%) (0) (0) (0)
Luo et al. BMC Cancer 2014, 14:653 Page 4 of 13
http://www.biomedcentral.com/1471-2407/14/65316.4% (122/742) received three-dimensional conformal
radiotherapy (3D-CRT) or intensity-modulated radio-
therapy (IMRT). The patients at early stages (stages I
and II) were treated using radiotherapy alone. The pa-
tients at advanced stages (stages III and IV) received
radiotherapy and combined neoadjuvant chemotherapy
and/or concurrent chemotherapy. The techniques of low
melting-point lead block, multi-leaf collimator (MLC),
thermoplastic mask and source axis distance (SAD) were
applied to radiotherapy. Cobalt-60 (Co-60) gamma-rays
or 6-8 MV supervoltage X rays generated by a linear ac-
celerator were used for external irradiation. The fractionof two-dimensional conformal radiotherapy was conven-
tional (2 Gy/F, 5 F/Week), and the dose for the primary
lesion in the nasopharynx was 66 ~ 76 Gy/33 ~ 38 F. The
dose for the cervical lymphatic drainage area was 50 ~
66 Gy/25 ~ 33 F. Cobalt-60 (Co-60) gamma-rays or
supervoltage X ray added beta-rays were used to com-
pensate the dose in consideration of skin and subcutane-
ous tissues in the neck. The prescribed radiation doses
of 3D-CRT were defined as follows [17]: GTVnx (naso-
pharynx gross tumor volume): 65-70 Gy; GTVnd (positive
neck lymph nodes volume): 60-70 Gy; CTV60 (clinical
target volume 60): 60 Gy; CTVnx50 (nasopharynx clinical
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target volume): 50 Gy. The prescribed radiation dose of
IMRT was defined as follows [18,19]: a total dose of 68 Gy
in 30 fractions at 2.27 Gy per fraction to the planning tar-
get volume (PTV) of the primary gross tumor volume
(GTV-P), 60 to 64 Gy to the PTV of nodal gross tumor
volume (GTV-N), 60 Gy to the PTV of CTV-1 (i.e., high-
risk regions), and 54 Gy to the PTV of CTV-2 (i.e., low-
risk regions) and CTV-N (i.e., neck nodal regions). The
treatment was delivered by a dynamic, multileaf, intensity-
modulating collimator (called MIMiC). For the lower
neck, an anterior cervical field was used. All patients were
treated with one fraction daily over 5 days per week. The
patients with residual tumor confined in the nasopharyn-
geal cavity after external irradiation would receive after-
loading irradiation of 2-3 F, 5 Gy/F. In this study, 73%
(542/742) of patients received platinum-based neoadju-
vant, concurrent, or adjuvant chemotherapy.
Patient follow-up
The duration of patient follow-up was calculated from
the first day of treatment to either the day of death or
the day of the last examination. The patients were exam-
ined at least every 3 months during the first 2 years;
thereafter, a follow-up examination (including nasophar-
yngoscopy, MRI of the head and neck, chest radiog-
raphy, and abdominal sonography) were performed
every 6 months for up to 5 years or until death.
All events were measured from the date of treatment
commencement. The following end points (time to the
first defining event) were assessed: overall survival (OS);
local relapse-free survival (LRFS); distant metastasis-free
survival (DMFS); and disease-free survival (DFS). The
OS was defined as the duration from the date of each
patient’s treatment commencement to the date of death
from any cause or the censoring of the patient at the
date of the last follow-up. The DFS was defined as the
duration from the date of treatment commencement to
the date of disease progression of the patient at the date
of the last follow-up. The LRRFS and DMFS were also
evaluated and calculated from the date of each patient’s
treatment commencement until the day of the first
locoregional or distant relapse or until the date of the
last follow-up visit. Local recurrence was determined by
endoscopy and biopsy or MRI. Distant metastases were
diagnosed on the basis of clinical symptoms, physical
examination, and imaging methods, including chest radi-
ography, bone scans, MRI and abdominal sonography.
As described in our previous paper [20].
Statistical analysis
The Statistical Package for Social Sciences, version 16.0
(SPSS Inc., Chicago, IL) was used. Actuarial rates were
calculated using the Kaplan–Meier method and differenceswere compared using the log-rank test. Multivariate
analyses using the Cox proportional hazards model were
used to calculate the hazard ratio (HR). The Cox pro-
portional hazards model was also used to test hazard
consistency and hazard discrimination. Host factors
(age and sex) and T classification were included as co-
variates in all tests. A two-tailed P value less than 0.05
was considered statistically significant.
Results
Follow-up outcomes
The time of last follow-up was July 2010, and the me-
dian follow-up period was 63.6 months. Of all 742 pa-
tients, 57 developed locoregional relapse including 47
cases of nasopharyngeal relapse and 10 cases of cervical
lymph node relapse. 92 patients developed distant me-
tastasis including 21 cases of bone metastasies, 15 cases
of liver metastasis, 13 cases of lung metastasis, 41 cases
of multi-organ metastasis, 1 case of auxiliary lymph
node metastasis and 1 case of vertebral canal metastasis.
The 5-year survival rates were as follows: OS, 80.5%;
DFS, 82.1%; LRFS, 92.3%; DMFS, 87.6%.
Patient characteristics categorized by masticator space
involvement
The incidence of MSI was 24.1% (179/742) and included
118 (15.9%) cases of grade 1, 38 (5.1%) cases of grade 2,
and 23 (3.1%) cases of grade 3 disease. Table 1 shows a
comparison of the patient characteristics, T and N classi-
fication, chemotherapy, and presence of MSI. A signifi-
cantly higher proportion of patients with MSI had
advanced T stage (P < 0.001). A correlation was also ob-
served between MSI and N stage (P = 0.047). There was
also correlation between chemotherapy strategy and MSI
(P < 0.001).
Masticator space involvement associated with more
aggressive tumor extension
Univariate analysis showed masticator space involvement
was associated with intracranial extension, tumor inva-
sion of prevertebral space, base of skull bony structure,
paranasal sinuses and parapharyngeal space (Table 2).
Masticator space involvement in general is an
independent prognostic factor for OS and DMFS
The 5-year OS for NPC patients with and without MSI
was 70.9% and 82.5%, respectively (P = 0.001; Figure 2A).
The 5-year LRFS for patients with and without MSI was
94.1% and 91.4%, respectively (P = 0.511; Figure 2B).
The 5-year DMFS was 81.4% and 88.7% for patients with
and without MSI, respectively (P = 0.021; Figure 2C).
The 5-year DFS was 78.0% and 83.5% for patients with
and without MSI, respectively (P = 0.215; Figure 2D).
Table 2 Association of primary tumor extension and MSI
Primary tumor extension
MSI - MSI +
No. % No. % P value
Intracranial 28 5.0 56 31.1 <0.001
Prevertebral space 213 38.0 156 86.7 <0.001
Base of skull bony structure 260 46.3 159 88.3 0.002
Paranasal sinuses 37 6.5 52 28.9 0.020
Parapharyngeal space 334 59.4 158 87.8 0.045
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IMRT. Patients treated with 3D-CRT/IMRT and patients
treated with conventional radiotherapy had been ana-
lyzed separately as following: (1) There were 122 cases
totally in 3D-CRT/IMRT population, 26 with MSI and
96 without MSI, giving an approximate ratio of 1:3. OS,
LRFS, DMFS and DFS of MSI group and non-MSI group
were estimated by Kaplan-Meier analysis and theFigure 2 Survival analyses for MSI. (A) Overall survival, (B) local relapse-
patients with MSI and patients without MSI. MSI, masticator space involvemdifferences of the survival probabilities were compared
by Log-rank test. The results showed statistically signifi-
cant differences in OS (P < 0.001), DMFS (P = 0.005)
and DFS (P = 0.017), while not in LRFS (P = 0.282). (2)
There were 620 cases totally in conventional radiother-
apy population, 154 with MSI and 466 without MSI, also
giving an approximate ratio of 1:3, just similar with 3D-
CRT/IMRT population. The same analyses were applied,
results showed statistically significant differences in OS
(P < 0.001), DMFS (P = 0.005) and DFS (P = 0.008), while
not in LRFS (P = 0.639). Overall, compared with patients
without MSI, patients with MSI had a worse prognosis
for OS and DMFS by univariate analysis.
Several parameters were included in the Cox propor-
tional hazards model, and multivariate analysis was
performed to adjust for various prognostic factors. The
included parameters were the following: age (≤46 y vs. >46 y),
gender (female vs. male), WHO histological grade (Typefree survival, (C) metastasis-free survival and (D) disease-free survival for
ent.
Table 3 Multivariate analysis of prognostic factors for NPC patients
Endpoint and Variable Factors P value Odds ratio*
Death Gender (female VS. male) 0.042 0.629(0.402,0.984)
Age (≤46 y VS >46 y) <0.0001 1.837(1.313,2.570)
MSI (with VS. without) <0.002 1.770(1.234,2.539)
N classification (N0-1 VS N2-3) <0.0001 2.035(1.428,2.901)
Local regional failure Gender (female VS. male) 0.052 0.455(0.206,1.006)
Distant failure MSI (with VS. without) 0.027 1.658(1.058,2.596)
N classification (N0-1 VS N2-3) <0.0001 2.828(1.849,4.326)
Disease failure N classification (N0-1 VS N2-3) <0.001 2.094(1.460,3.002)
*Data in parentheses are 95% confidence intervals.
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3), chemotherapy (with vs. without), radiation therapy
technique (two-dimensional conventional radiation ther-
apy vs. three-dimensional conformal radiation therapy vs.
intensity-modulated radiation therapy), and MSI (with vs.
without). The OS, LRFS, DMFS and DFS were evaluated
as endpoints. T stage has a positive correlation with MSI
(R = 0.379, P < 0.001), and the correlation is significant at
the 0.01 level (2-tailed). T stages will cover MSI when they
are both included in multivariate analysis. Therefore, we
analyzed these parameters separately. When T stage was
included with MSI the independent prognostic factors for
OS were age, T stage and N stage. The independent prog-
nostic factor for LRFS was T stage. The T stage and N
stage were also independent prognostic factors for both
DMFS and DFS. When MSI was included without T
stages, the independent prognostic factors for OS wereTable 4 Multivariate analysis of prognostic factors for NPC pa
OS LRFS






T stage <0.001 - 0.004 -
N stage <0.001 -
MSI grade 0.041* (1.162,4.402) 0.258
Pattern B
Age <0.001 -
T stage <0.001 - <0.001 -
N stage <0.001 -
MSI grade 0.018* (1.148,4.226) 0.504
Pattern C
Age <0.001 -
T stage <0.001 - 0.004 -
N stage <0.001 -
MSI grade 0.007* (1.289,4.895) 0.209
*Data are statistically significant in terms of MSI.gender, age, N stage and MSI. Both MSI and N stage were
independent prognostic factors for DMFS and N stage
was an independent prognostic factor for DFS (Table 3).
Thus, MSI was an independent prognostic factor for OS
and DMFS.
Involvement of infratemporal fossa was an unfavorable
independent prognostic factor
Whether different MSI involvement grade has prognos-
tic value is still not clear. We further investigated if there
is a more appropriate classification for MSI in terms of
its prognostic value. According to the different grades of
MSI, three categories were listed by permutation and
combination:
Classification pattern A: grade 0 converted to PA0,
grade 1 converted to PA1, grade 2 converted to PA2, grade




P value Hazard ratio
(95% CI)
P value Hazard ratio
(95% CI)
<0.001 - <0.001 -
<0.001 - <0.001 -
0.394 0.638
<0.001 - <0.001 -
<0.001 - <0.001 -
0.112 0.273
<0.001 - <0.001 -
<0.001 - <0.001 -
0.169 0.331
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converted to PB0, grade 3 converted to PB1.
Classification pattern C: grade 0 converted to PC0,
grade 1 and grade 2 converted to PC1, grade 3 converted
to PC2.
Multivariate analysis was applied using a Cox regres-
sion model in each MSI classification pattern to identify
prognostic factors for OS, LRFS, DMFS and DFS. The
analyses revealed that classification patterns A, B and C
showed MSI grade was an independent prognostic factor
for OS (P < 0.041 in pattern A, P = 0.018 in pattern B,
P = 0.007 in pattern C), but not for LRFS, DMFS and
DFS. The other independent prognostic factors were not
changed and these factors are presented in Table 4. The
OS, LRFS, DMFS, and DFS curves for different groups
of MSI in patterns A, B and C are shown in Figures 3, 4
and 5. Based on the Cox regression model in pattern A,Figure 3 Survival analyses for MSI Pattern A. (A) Overall survival, (B) loc
survival for different groups of MSI in pattern A. MSI, masticator space invo
converted to PA1, grade 2 converted to PA2, grade 3 converted to PA3. Gr
with medial pterygoid muscle involvement but without lateral pterygoid m
medial and/or lateral pterygoid muscle but without infratemporal fossa invit was suggested that each grade of MSI might influence
OS of the patients. Both classification patterns B and C
indicate that involvement of infratemporal fossa (IFI)
had a worse OS than involvement of medial pterygoid
and/or lateral pterygoid (MLPI). In pattern C, we also
found that IFI has a worse DMFS than MLPI (P =
0.035). In patterns A and B, we also found a similar
trend (P = 0.081 in pattern A, P = 0.066 in pattern B).
Involvement of medial/lateral pterygoid muscle only
should be classified as T3, and infratemporal fossa
involvement should be classified as T4
Based on our results, we propose that IFI should be sep-
arated from MLPI and be classified into a higher T stage.
Alternatively, MLPI should be adjusted to a lower T
stage. We further evaluated this proposal by performing
two comparisons. We compared MLPI versus T3al relapse-free survival, (C) metastasis-free survival and (D) disease-free
lvement. Classification pattern A: grade 0 converted to PA0, grade 1
ades of masticator space involvement. Grade 0: without MSI; Grade 1:
uscle involvement or infratemporal fossa involvement; Grade 2: with
olvement; Grade 3: with infratemporal fossa involvement.
Figure 4 Survival analyses for MSI Pattern B. (A) Overall survival, (B) local relapse-free survival, (C) metastasis-free survival and (D) disease-free
survival for different groups of MSI in pattern B. MSI, masticator space involvement. Classification pattern B: grade 0, grade 1 and grade 2 converted to
PB0, grade 3 converted to PB1. Grades of masticator space involvement. Grade 0: without MSI; Grade 1: with medial pterygoid muscle involvement but
without lateral pterygoid muscle involvement or infratemporal fossa involvement; Grade 2: with medial and /or lateral pterygoid muscle but without
infratemporal fossa involvement; Grade 3: with infratemporal fossa involvement.
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and/or paranasal sinus involvement. We also compared
IFI versus all other situations of T4 including intracranial
involvement, cranial nerves and/or orbit involvement.
In the first comparison, the OS between MLPI and T3
did not show a significant difference (P = 0.998), nor did
DMFS and DFS (P = 0.876, 0.223, respectively). LRFS re-
sulted in a trend that MLPI and T3 might be different
but that this result was not significant (P = 0.079). The
survival curves of OS, LRFS, DMFS and DFS are shown
in Figure 6.
The second comparison of IFI and the rest of T4 pre-
sented a similar outcome with no significant differences
between these two groups in OS, LRFS, DMFS and DFS
(P = 0.311, 0.332, 0.747, 0.821, respectively). The survivalcurves of OS, LRFS, DMFS and DFS are shown in Figure 7.
Therefore, we validated that MLPI only should be clas-
sified as T3, and IFI should be classified as T4.
Then we carried out two comparisons in 3D-CRT/
IMRT population alone, T3 (without MSI) vs. MLPI, and
T4 vs. IFI, according to the analysis pattern of the entire
sample. In the comparison of T3 (without MSI) and
MLPI, there were 40 cases in T3 group and 20 cases in
MLPI group. The OS, LRFS, DMFS and DFS between
T3 and MLPI did not displayed any significant differ-
ence (P = 0.693, 0.804, 0.270, 0.754, respectively). In the
comparison of T4 and IFI, there were 11 cases in T4
group and 7 cases in IFI group. The OS, LRFS, DMFS
and DFS between T4 and IFI did not displayed any signifi-
cant difference (P = 0.739, 0.254, 0.971, 0.441, respectively),
Figure 5 Survival analyses for MSI pattern C. (A) Overall survival, (B) local relapse-free survival, (C) metastasis-free survival and (D) disease-free
survival for different groups of MSI in pattern C. MSI, masticator space involvement. Classification pattern C: grade 0 converted to PC0, grade 1
and grade 2 converted to PC1, grade 3 converted to PC2. Grades of masticator space involvement. Grade 0: without MSI; Grade 1: with medial
pterygoid muscle involvement but without lateral pterygoid muscle involvement or infratemporal fossa involvement; Grade 2: with medial and
/or lateral pterygoid muscle but without infratemporal fossa involvement; Grade 3: with infratemporal fossa involvement.
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http://www.biomedcentral.com/1471-2407/14/653either. Results like this might possibly indicate MLPI should
be classified as T3 and IFI should be classified as T4 both
in 3D-CRT/IMRT population and conventional radiother-
apy population.
Discussion
In the present study, we observed that MSI grade was an
independent prognostic factor for OS and DMFS. When
the tumor invades beyond the lateral pterygoid muscle
and into the infratemporal fossa, it independently indi-
cated shorter OS and DMFS. This demonstrated that
grading MSI as MLPI and IFI may be a valuable progno-
sis indicator in NPC. The reason for the patients with
IFI have a significantly higher risk of distant failure than
in patients with MLPI might be a bulky primary tumor
can lead to tumor invasion into the venous plexus,thereby increasing the risk of hematogenous dissemin-
ation. At the same time, MSI correlated with advanced
N classifications as shown in Table 1. These results sug-
gest that severe MSI has a potential to distant spreading.
The present study also revealed that anatomic mastica-
tor space involvement was significantly associated with
tumor infiltration at the base of the skull, in paranasal
sinuses, intracranial, prevertebral space, and parapharyn-
geal space. This is consistent with the previous study by
Liang et al. [21] in which local disease spread stepwise
from proximal sites to distal sites in NPC is observed.
Several investigators have also reported that a larger
tumor volume is associated with an increased rate of
tumor recurrence and poor patient survival rates [22,23].
The reason no MSI pattern influenced LRFS or DFS
might be due to the intensive use of MRI with high-
Figure 6 Survival analyses for patients with T3 (UICC) VS patients with MLPI. (A) Overall survival, (B) local relapse-free survival, (C)
metastasis-free survival and (D) disease-free survival for patients with stage T3 and patients with medial and/or lateral pterygoid muscle involve-
ment. MLPI, medial and/or lateral pterygoid involvement.
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ume recognition. Conversely, the dose distribution was
improved by 3D-CRT and IMRT, which provided good
local control. Consequently, MSI and some local exten-
sions that previously influenced LRFS may be less useful
with current technology.
AJCC 7th TNM staging system for NPC refers the in-
volvement any part of the entire masticator space as T4.
However, the 2008 Chinese TNM staging system defined
involvement of medial pterygoid as T3 and the involve-
ment of the lateral region of medial pterygoid in the
masticator space as T4. As several versions of TNM sta-
ging systems for NPC arise, there will be additional
studies attempting to determine which MSI stage is ap-
propriate and how MSI influences survival. A study of
the 2008 Chinese TNM staging system performed by
Mao YP et al. [24] reported in 2009 that the risk of localfailure of medial pterygoid involvement was close to the
risk of local failure of intracranial extension/cranial
nerve involvement and cavernous sinus involvement.
The study suggested T4 should include medial ptery-
goid involvement. Sun Y et al. [25] demonstrated that
LRFS of medial pterygoid involvement was worse than
that of base of skull bony structure (T3), which is con-
sistent with AJCC 7th staging system for NPC. Tang LL
et al [10] revealed that anatomic masticator space in-
volvement affected the OS and LRFS of patients with
NPC and they recommended that anatomic masticator
space involvement that includes the medial and lateral
pterygoid muscles be classified as stage T4 disease.
The results of our study demonstrated that patients with
IFI had a poorer overall survival compared to MLPI pa-
tients. Additionally, there were homogeneous survival
rates between MLPI and T3, IFI and the rest of T4 disease.
Figure 7 Survival analyses for patients with T4 (UICC) without IFI VS patients with IFI. (A) Overall survival, (B) local relapse-free survival,
(C) metastasis-free survival and (D) disease-free survival for patients with stage T4 without infratemporal fossa involvement and patients with
infratemporal fossa involvement. IFI, infratemporal fossa involvement.
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difference, nor did IFI and T4. So we suggested that MLPI
should be distributed into T3 disease and IFI distributed
into T4 disease. Our findings will help to reevaluate the
present TNM staging systems for NPC including the
AJCC 7th and 2008 Chinese systems. Our results provide
suggestions and options to improve the T staging system
by classifying MLPI as T3 and IFI as T4 disease.
A new T staging system based on this study of
MSI and the revised definition of T3/T4 could be
used for medical management. Patients with IFI
should be separately evaluated from patients with
MLPI. It might be useful to identify the high-risk
group from within all MSI patients to allow adjust-
ments of treatment strategy. Additional studies are
required to observe the efficacy of this modified T
staging classification.
There are some limitations in the current retrospective
study. One limitation was the different radiationmodalities in our patient cohort and the other was the
use of different chemotherapy modalities. The use of
IMRT has provided encouraging results [26-28]. IMRT
is the main radiation modality for NPC in our cancer
center and worldwide now. But at that time (2005),
due to unavoidable economic limitations, only 122
(16.4%) patients in our cohort underwent 3D-CRT/
IMRT. Thus, to confirm our scientific findings, a pro-
spective study with a relatively large cohort treated by
IMRT is warranted. We believe that with the prevailing
use of IMRT worldwide, some prognostic factors for
NPC patients could be changed.
Conclusions
MSI was an independent prognostic factor for OS and
DMFS. NPCs invading the masticator space should be
separately categorized into MLPI and IFI groups. Our
data suggest that MLPI should be staged as T3 while IFI
is staged as T4 in future TNM staging revisions.
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